Squarepoint’s NanoViricides NNVC Stock Holding History

Squarepoint’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-58,138	Closed	-$53K	–	4795
2026 Q1	$53K	Buy	+58,138	New	+$60.8K	﹤0.01%	4136

Other funds holding NNVC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint's NNVC Position: Q2 2026 in Review

Squarepoint sold out of NanoViricides (NNVC) in Q2 2026, closing a stake of 58,138 shares — an estimated $53K sold.

Squarepoint first reported a position in NNVC in Q1 2026 and held it in 1 quarter. The position peaked at $53K in Q1 2026. 48 funds tracked by Wall St. Rank hold NNVC as of Q2 2026.

Squarepoint reported no remaining NanoViricides position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 58,138 NanoViricides shares in Q2 2026, an estimated $53K.
Squarepoint first reported a position in NanoViricides in Q1 2026 and held it in 1 quarter.
Squarepoint's NanoViricides position peaked at $53K in Q1 2026.
48 funds tracked by Wall St. Rank held NanoViricides as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.